Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are important causes of chronic liver disease in the United States. The NASH Clinical Research Network (NASH CRN) was established in 2002 to conduct research related to its clinical features, risk factors, pathogenesis, natural history and treatment in children and adults. The initial funding period of the NASH CRN has been very productive in establishing and conducting network-wide protocols and numerous ancillary and pilot studies. Encouraged by its success, the NIDDK has issued RFA-DK-08-505 whose objective is to continue the NASH CRN for additional five years, The objectives of the NASH CRN during the next funding period are (a) to successfully complete the 3 network-wide studies initiated during the initial funding period. These include the observational longitudinal study of NAFLD in adults and children (NAFLD Database study, n=l,215), a randomized double blind controlled therapeutic study in adult non diabetic patients with NASH (PIVENS, n=247), and a randomized double blind controlled therapeutic study in children with NASH (TONIC, n=173). The NAFLD Database study will be amended to meet additional goals during the next funding period. These modifications may include extending the length of follow-up of those enrolled, consideration of a follow-up liver biopsy in a subset of patients without cirrhosis for better assessment of histological natural history and enrolling carefully chosen controls without NAFLD (b) to successfully complete the ancillary and pilot studies that have been begun during the initial funding period, (c) to conduct additional therapeutic studies in adults and children with NASH since currently available options to treat NASH are limited. Subsets of patients requiring immediate attention include (but not limited) to those with diabetes because of the higher prevalence and greater severity of disease (d) to initiate and complete additional ancillary studies based on extensive clinical material and biosamples collected thus far. In the present funding period, we propose to complete the specific aims stated above and additionally conduct 2 clinical trials using S adenosyl L-methionine and pentoxifylline, based on sound pathophysiological rationale developed during the initial funding period.

Public Health Relevance

NAFLD is the commonest liver disease in North America affecting both children and a third of adults. NASH is a severe form of NAFLD and a significant clinical component of the metabolic syndrome. At least 15% of patients with NASH will progress to develop cirrhosis in an estimated 6 milion Americans. The societal and economic costs of this disease burden provide a compelling public health rationale for the proposed studies.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (M1))
Program Officer
Doo, Edward
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cleveland Clinic Lerner
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Dasarathy, Srinivasan (2016) Cause and management of muscle wasting in chronic liver disease. Curr Opin Gastroenterol 32:159-65
Dasarathy, Srinivasan (2016) Nutrition and Alcoholic Liver Disease: Effects of Alcoholism on Nutrition, Effects of Nutrition on Alcoholic Liver Disease, and Nutritional Therapies for Alcoholic Liver Disease. Clin Liver Dis 20:535-50
Davuluri, Gangarao; Allawy, Allawy; Thapaliya, Samjhana et al. (2016) Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. J Physiol 594:7341-7360
Nelson, J E; Handa, P; Aouizerat, B et al. (2016) Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Aliment Pharmacol Ther 44:1253-1264
Schwimmer, Jeffrey B; Lavine, Joel E; Wilson, Laura A et al. (2016) In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology 151:1141-1154.e9
Dasarathy, Srinivasan; Merli, Manuela (2016) Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 65:1232-1244
Dasarathy, Srinivasan; Dasarathy, Jaividhya; Khiyami, Amer et al. (2016) In Response. J Clin Gastroenterol 50:181
Kanwar, Pushpjeet; Nelson, James E; Yates, Katherine et al. (2016) Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol 3:e000114
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Bazick, Jessica; Donithan, Michele; Neuschwander-Tetri, Brent A et al. (2015) Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care 38:1347-55

Showing the most recent 10 out of 79 publications